Alaunos Therapeutics TCRT Stock
Alaunos Therapeutics Price Chart
Alaunos Therapeutics TCRT Financial and Trading Overview
| Alaunos Therapeutics stock price | 2.68 USD |
| Previous Close | 2.91 USD |
| Open | 2.88 USD |
| Bid | 2.47 USD x 100 |
| Ask | 3.36 USD x 100 |
| Day's Range | 2.84 - 2.88 USD |
| 52 Week Range | 2.11 - 33 USD |
| Volume | 1.98K USD |
| Avg. Volume | 14.78K USD |
| Market Cap | 4.6M USD |
| Beta (5Y Monthly) | -0.493 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.92 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TCRT Valuation Measures
| Enterprise Value | 2.08M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.787667 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 657.1073 |
| Price/Book (mrq) | 1.2197877 |
| Enterprise Value/Revenue | 297.794 |
| Enterprise Value/EBITDA | -0.166 |
Trading Information
Alaunos Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.493 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 33 USD |
| 52 Week Low | 2.11 USD |
| 50-Day Moving Average | 4.89 USD |
| 200-Day Moving Average | 12.5 USD |
TCRT Share Statistics
| Avg. Volume (3 month) | 14.78K USD |
| Avg. Daily Volume (10-Days) | 20.3K USD |
| Shares Outstanding | 1.6M |
| Float | 1.31M |
| Short Ratio | 6.3 |
| % Held by Insiders | 14.29% |
| % Held by Institutions | 15.13% |
| Shares Short | 144.06K |
| Short % of Float | 10.44% |
| Short % of Shares Outstanding | 9.00% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | June 30, 2024 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -29150.00000000000000000000000000000000% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -51.76% |
| Return on Equity (ttm) | -150.49% |
Income Statement
| Revenue (ttm) | 7K USD |
| Revenue Per Share (ttm) | 0.004 USD |
| Quarterly Revenue Growth (yoy) | 0% |
| Gross Profit (ttm) | N/A |
| EBITDA | -12579000 USD |
| Net Income Avi to Common (ttm) | -19129000 USD |
| Diluted EPS (ttm) | -319.97 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.46M USD |
| Total Cash Per Share (mrq) | 1.54 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.158 |
| Book Value Per Share (mrq) | 2.355 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -17357000 USD |
| Levered Free Cash Flow (ttm) | -11826750 USD |
Profile of Alaunos Therapeutics
| Country | United States |
| State | TX |
| City | Houston |
| Address | 2617 Bissonnet Street |
| ZIP | 77005 |
| Phone | 346 355 4099 |
| Website | https://www.alaunos.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1 |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Q&A For Alaunos Therapeutics Stock
What is a current TCRT stock price?
Alaunos Therapeutics TCRT stock price today per share is 2.68 USD.
How to purchase Alaunos Therapeutics stock?
You can buy TCRT shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alaunos Therapeutics?
The stock symbol or ticker of Alaunos Therapeutics is TCRT.
Which industry does the Alaunos Therapeutics company belong to?
The Alaunos Therapeutics industry is Biotechnology.
How many shares does Alaunos Therapeutics have in circulation?
The max supply of Alaunos Therapeutics shares is 1.64M.
What is Alaunos Therapeutics Price to Earnings Ratio (PE Ratio)?
Alaunos Therapeutics PE Ratio is now.
What was Alaunos Therapeutics earnings per share over the trailing 12 months (TTM)?
Alaunos Therapeutics EPS is -2.92 USD over the trailing 12 months.
Which sector does the Alaunos Therapeutics company belong to?
The Alaunos Therapeutics sector is Healthcare.
Alaunos Therapeutics TCRT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17166.04 USD — |
+2.74
|
6.86B USD — | 16744.97 USD — | 17174.35 USD — | — - | 6.86B USD — |
| NASDAQ Global Select Market Com NQGS | 8392.2 USD — |
+2.74
|
— — | 8186.56 USD — | 8396.52 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4190.58 USD — |
+1.81
|
— — | 4101.67 USD — | 4190.75 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 930.32 USD — |
+2.05
|
— — | 911.02 USD — | 930.5 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4126.44 USD — |
+0.05
|
— — | 3927.42 USD — | 4126.44 USD — | — - | — — |
- {{ link.label }} {{link}}